Business Context and Reporting Period
Company: ImmuCell Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2003
Business Overview: The Company operates in a single segment focused on the development, acquisition, manufacture, and sale of products to improve the health and productivity of cows for the dairy and beef industry. Primary customers are in the United States (95% of product sales in Q1 2003).
Key Financial Metrics
| Metric | Q1 2003 | Q1 2002 |
|---|---|---|
| Total Revenues | $1,127,292 | $1,896,674 |
| Product Sales | $1,015,552 | $1,778,657 |
| Net Operating Income | $69,944 | $288,228 |
| Net Income | $701,490 | $169,055 |
| Diluted EPS | $0.25 | $0.06 |
| Cash and Equivalents (Ending) | $3,877,866 | $1,969,143 |
| Short-term Investments | $495,543 | $787,046 |
| Total Assets | $8,276,277 | $7,513,393 |
| Net Working Capital | $5,472,717 | $4,227,642 |
| Debt | $0 | $0 |
Margins: Gross margin on product sales was 58% in Q1 2003 compared to 52% in Q1 2002. The effective income tax rate was 41% for both periods.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 41% ($769,000) and product sales decreased 43% ($763,000). This was primarily due to the early termination of a product license (Kamar Heatmount Detector) effective October 1, 2002, which had generated $727,000 in sales in Q1 2002.
- Net Income Surge: Despite lower operating income, Net Income increased 315% to $701,490. This was driven by a non-recurring gain of $1,100,000 recorded as "Other Income" from the sale of the Company's 50% interest in the AgriCell Company, LLC joint venture.
- Expense Fluctuations:
- R&D Expenses: Increased 58% to $315,537, largely due to $104,000 in outside laboratory expenses for the clinical trial stage of the "Mast Out" product.
- Sales & Marketing: Decreased 57% to $167,334, reflecting the removal of costs associated with the terminated license.
- Liquidity: Cash and cash equivalents increased by $1,521,896 during the quarter. Net working capital increased by $1,245,000.
Guidance, Outlook, and Risks
- Product Development: The Company is advancing "Mast Out," a non-antibiotic treatment for mastitis in dairy cows. Management anticipates continued profitable operations annually but notes that high development costs for Mast Out could temporarily impact quarterly profitability objectives in 2003.
- Deferred Revenue: The Company holds $350,000 in deferred revenue from a State of Maine Development Award for Mast Out. This funding has a contingent payback obligation: either a lump sum repayment within two years of commercialization or a 2% royalty on sales (capped at 2x the grant amount).
- Market Risks: Sales are negatively affected by the decline in milk prices earned by primary customers. Foreign sales dropped to 2% of product sales in Q1 2003 from 25% in Q1 2002.
- Stock Repurchase: On April 3, 2003, the Board approved a plan to repurchase up to 100,000 shares (approx. 3.7% of outstanding stock). As of May 12, 2003, 5,100 shares had been repurchased for approximately $10,600.
- Forward-Looking Statements: Management cautions that actual results may differ due to regulatory approval delays, production issues, and competition.
Investor Verification Checklist
- Non-Recurring Income: Verify the sustainability of earnings by excluding the $1.1 million one-time gain from the AgriCell joint venture sale.
- Operating Profitability: Assess the core business health by focusing on the $69,944 Net Operating Income, which represents a significant decline from the prior year's $288,228.
- R&D Burn Rate: Monitor the $315,537 R&D spend and the specific $104,000 external lab costs for Mast Out to ensure they align with development milestones.
- Deferred Revenue Obligations: Review the terms of the $350,000 Maine grant to understand future cash outflow risks upon commercialization.
- Seasonality: Note that sales of key products like "First Defense" are seasonal, with higher volumes expected in winter months.